A Phase 2 interventional study of STP705 in Basal Cell Carcinoma, sponsored by Sirnaomics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Sirnaomics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.
Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 80th largest by enrollment of the 139 interventional ones that give a count, is one of 8 that started in 2020, is one of 46 in phase 2, and was the 122nd registered.
389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.
Browse Carcinoma, Basal Cell studies →23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Philogen S.p.A. · Sites in United States, Germany, Greece and 2 more countries
Ages 18+
Philogen S.p.A. · Sites in United States, Germany, Greece and 2 more countries
Ages 18+
University of Rochester · Sites in United States
University of Rochester · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 52 Carcinoma, Basal Cell studies recruiting now, 48 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 58 · Phase 3 7 · Phase 4 5
First in 1977; this study’s year is marked. 8 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 50 across 272 interventional studies indexed under Carcinoma, Basal Cell.
Median enrollment 40 across the 139 interventional studies, 80 across the 26 observational. Of the 119 that completed or were terminated, 48 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 171 have an industry lead sponsor. The 10 most frequent:
Sirnaomics is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 2 (22%) have results posted.
Sirnaomics has 1 study filed under Carcinoma, Basal Cell — fewer than ten, so there is no comparison to draw.
19 of the studies in Carcinoma, Basal Cell with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06608511University of Wisconsin, MadisonLiquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers | 2026-12 |
| NCT06623201Nathalie ZeitouniBlue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas | 2026-12-01 |
| NCT04616248University of Southern CaliforniaIn Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | 2027-01-09 |
| NCT06384924Tiezhi ZhangRaman Spectroscopy and Skin Cancer | 2027-02-13 |
| NCT05294120Memorial Sloan Kettering Cancer CenterA Study on Radiation Therapy Guided by the Reflectance Confocal Microscopy (RCM)/Optical Coherence Tomography (OCT) Device in People With Basal Cell Carcinoma | 2027-03 |
Add all 19 to your calendar (.ics) → With an account.
Among the 171 studies in Carcinoma, Basal Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with Basal Cell Carcinoma (BCC).
Goals:
Basal cell carcinoma occurs most often on areas of the skin that are exposed to the sun, such as head and neck. The most commonly found clinical feature of Basal Cell Carcinoma (BCC) is an elevated tumor with a pearly and translucent margin and telangiectasia. The color may vary widely from nearly normal skin color to erythematous to violaceous and may also be pigmented. BCC may also resemble noncancerous skin conditions such as eczema or psoriasis. The majority of these cancers occur on areas of skin that are regularly exposed to sunlight or other ultraviolet radiation.
The STP705 drug substance (STP705) is composed of two siRNA oligonucleotides, targeting the expression of TGF-β1 and Cox-2 mRNA respectively. Along with the HKP-enhanced delivery system, the combination is expected to downregulate TGF-β1 and COX-2 expression resulting in the inhibition of tumor growth and provide an alternative non-invasive approach for the treatment of BCC.
This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with BCC. This study seeks to establish a safe and effective recommended dose of STP705 for the treatment of BCC. The clinician will evaluate the change in tumor size at each treatment visit. At the End of Treatment visit, the residual tumor, or former tumor location, will be excised for analysis. Expression of biomarkers common to the BCC formation pathway, including TGF-β1 and COX-2, will be evaluated.
Safety and tolerability will be assessed by the number of incidence of adverse events (AEs) and serious adverse events (SAEs); the incidence of AEs and SAEs leading to discontinuation of trial medication; the incidence and severity of Local Skin Response (LSR); hypopigmentation and hyperpigmentation following treatment; and the tolerability of repeated localized administration of STP705 as assessed by investigator-evaluation of injection site reactions for all patients and within each cohort.
The study plans to enroll approximately 35 adult patients at up to 3 clinical sites in the United States. The 35 patients will be divided equally among 7 cohorts (30, 60, 90, 120, 180, 240, and 320 μg dose level) of 5 patients each.
Inclusion Criteria: Subjects are required to meet all of the following criteria for enrollment into the study:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort A: STP705 30 μg dose, localized injection, given once a week for 6 weeks
Drug: STP705
Cohort B: STP705 60 μg dose, localized injection, given once a week for 6 weeks
Drug: STP705
Cohort C: STP705 90 μg dose, localized injection, given once a week for 6 weeks
Drug: STP705
Cohort D: STP705 120 μg dose, localized injection, given once a week for 6 weeks
Drug: STP705
Cohort E: STP705 180 μg dose, localized injection, given once a week for 6 weeks
Drug: STP705
Cohort F: STP705 240 μg dose, localized injection, given once a week for 6 weeks
Drug: STP705
Cohort G: STP705 320 μg dose, localized injection, given once a week for 6 weeks
Drug: STP705
Dry powder for intra-and peri-lesional injection.
Also known as: STP705 Powder for Injection
Proportion of Participants With Histological Clearance of Treated Basal Cell Carcinoma Lesion at the End of Treatment (EOT)
Histological clearance (HC) will be defined as the absence of detectable evidence of BCC tumor cell nests as determined by central pathology review.
Time frame: 6 weeks
Change in Clinical Diameter of the Treated Basal Cell Carcinoma Lesion Over the 6 Week Treatment Period
A baseline assessment of lesion clinical diameter will be made by investigator at T1 (first visit). The change in size from baseline to the End of Treatment (EOT) visit (Week 6) will be reported.
Time frame: End of Treatment (EOT) visit (Week 6)
| Milestone | Cohort A: STP705 30 μg Dose | Cohort B: STP705 60 μg Dose | Cohort C: STP705 90 μg Dose | Cohort D: STP705 120 μg Dose | Cohort E: STP705 180 μg Dose | Cohort F: STP705 240 μg Dose | Cohort G: STP705 320 μg Dose |
|---|---|---|---|---|---|---|---|
| Started | 5 | 5 | 6 | 6 | 5 | 5 | 0 |
| Completed | 5 | 5 | 5 | 5 | 5 | 5 | 0 |
| Not completed | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
Histological clearance (HC) will be defined as the absence of detectable evidence of BCC tumor cell nests as determined by central pathology review.
| Participants | Cohort A: STP705 30 μg Dose | Cohort B: STP705 60 μg Dose | Cohort C: STP705 90 μg Dose | Cohort D: STP705 120 μg Dose | Cohort E: STP705 180 μg Dose | Cohort F: STP705 240 μg Dose |
|---|---|---|---|---|---|---|
| Proportion of Participants With Histological Clearance of Treated Basal Cell Carcinoma Lesion at the End of Treatment (EOT) | 1 | 3 | 3 | 2 | 5 | 3 |
A baseline assessment of lesion clinical diameter will be made by investigator at T1 (first visit). The change in size from baseline to the End of Treatment (EOT) visit (Week 6) will be reported.
| millimeters (mm) | Cohort A: STP705 30 μg Dose | Cohort B: STP705 60 μg Dose | Cohort C: STP705 90 μg Dose | Cohort D: STP705 120 μg Dose | Cohort E: STP705 180 μg Dose | Cohort F: STP705 240 μg Dose |
|---|---|---|---|---|---|---|
| Change in Clinical Diameter of the Treated Basal Cell Carcinoma Lesion Over the 6 Week Treatment Period | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | -0.6 (-2.0 to 0) |
Collected over from enrollment until end of follow-up, up to 10 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: STP705 30 μg Dose | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Cohort B: STP705 60 μg Dose | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Cohort C: STP705 90 μg Dose | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Cohort D: STP705 120 μg Dose | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Cohort E: STP705 180 μg Dose | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Cohort F: STP705 240 μg Dose | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Cohort G: STP705 320 μg Dose | — | — | — |
| Event | Cohort A: STP705 30 μg Dose | Cohort B: STP705 60 μg Dose | Cohort C: STP705 90 μg Dose | Cohort D: STP705 120 μg Dose | Cohort E: STP705 180 μg Dose | Cohort F: STP705 240 μg Dose | Cohort G: STP705 320 μg Dose |
|---|---|---|---|---|---|---|---|
| ChillsGeneral disorders | 1/5 | 0/5 | 0/6 | 0/6 | 0/5 | 0/5 | — |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/5 | 1/5 | 0/6 | 0/6 | 0/5 | 0/5 | — |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/5 | 1/5 | 0/6 | 0/6 | 0/5 | 0/5 | — |
| HeadacheNervous system disorders | 0/5 | 1/5 | 0/6 | 0/6 | 0/5 | 0/5 | — |
| Skin LacerationInjury, poisoning and procedural complications | 0/5 | 0/5 | 0/6 | 0/6 | 1/5 | 0/5 | — |
| Atrial FibrillationCardiac disorders | 0/5 | 0/5 | 0/6 | 0/6 | 1/5 | 0/5 | — |
| DizzinessNervous system disorders | 0/5 | 0/5 | 1/6 | 0/6 | 0/5 | 0/5 | — |
| PyrexiaGeneral disorders | 0/5 | 0/5 | 1/6 | 0/6 | 0/5 | 0/5 | — |
| Staphylococcal Skin InfectionInfections and infestations | 0/5 | 0/5 | 1/6 | 0/6 | 0/5 | 0/5 | — |
| Aspartate Aminotransferase IncreasedInvestigations | 0/5 | 0/5 | 0/6 | 1/6 | 0/5 | 0/5 | — |
The study was closed by the sponsor prior to Cohort G, STP705 320 μg dosing.
| Age, Categorical(Participants) | Cohort A: STP705 30 μg Dose | Cohort B: STP705 60 μg Dose | Cohort C: STP705 90 μg Dose | Cohort D: STP705 120 μg Dose | Cohort E: STP705 180 μg Dose | Cohort F: STP705 240 μg Dose | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 4 | 1 | 3 | 2 | 3 | 15 |
| >=65 years | 3 | 1 | 5 | 3 | 3 | 2 | 17 |
| Age, Continuous(years) | Cohort A: STP705 30 μg Dose | Cohort B: STP705 60 μg Dose | Cohort C: STP705 90 μg Dose | Cohort D: STP705 120 μg Dose | Cohort E: STP705 180 μg Dose | Cohort F: STP705 240 μg Dose | Total |
|---|---|---|---|---|---|---|---|
| Median | 69 (51 to 76) | 58 (46 to 75) | 71 (39 to 95) | 67.5 (52 to 75) | 73 (49 to 80) | 60 (46 to 85) | 69 (39 to 95) |
| Sex: Female, Male(Participants) | Cohort A: STP705 30 μg Dose | Cohort B: STP705 60 μg Dose | Cohort C: STP705 90 μg Dose | Cohort D: STP705 120 μg Dose | Cohort E: STP705 180 μg Dose | Cohort F: STP705 240 μg Dose | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 4 | 3 | 2 | 1 | 3 | 14 |
| Male | 4 | 1 | 3 | 4 | 4 | 2 | 18 |
| Race (NIH/OMB)(Participants) | Cohort A: STP705 30 μg Dose | Cohort B: STP705 60 μg Dose | Cohort C: STP705 90 μg Dose | Cohort D: STP705 120 μg Dose | Cohort E: STP705 180 μg Dose | Cohort F: STP705 240 μg Dose | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 5 | 5 | 6 | 6 | 5 | 5 | 32 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A: STP705 30 μg Dose | Cohort B: STP705 60 μg Dose | Cohort C: STP705 90 μg Dose | Cohort D: STP705 120 μg Dose | Cohort E: STP705 180 μg Dose | Cohort F: STP705 240 μg Dose | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 5 | 5 | 6 | 5 | 5 | 5 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort A: STP705 30 μg Dose | Cohort B: STP705 60 μg Dose | Cohort C: STP705 90 μg Dose | Cohort D: STP705 120 μg Dose | Cohort E: STP705 180 μg Dose | Cohort F: STP705 240 μg Dose | Total |
|---|---|---|---|---|---|---|---|
| United States | 5 | 5 | 6 | 6 | 5 | 5 | 32 |
| Longest Diameter of Lesion (mm)(millimeters (mm)) | Cohort A: STP705 30 μg Dose | Cohort B: STP705 60 μg Dose | Cohort C: STP705 90 μg Dose | Cohort D: STP705 120 μg Dose | Cohort E: STP705 180 μg Dose | Cohort F: STP705 240 μg Dose | Total |
|---|---|---|---|---|---|---|---|
| Mean | 11.8 (6.0 to 18.0) | 11.8 (9.0 to 14.0) | 11.2 (7.0 to 17.0) | 10.0 (6.0 to 13.0) | 10.0 (6.0 to 13.0) | 10.8 (5.0 to 19.0) | 10.9 (5.0 to 19.0) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in Feb 2023, 25 months.
Results were first posted in Sep 2026, 3 years 7 months after primary completion.
Of 43 phase 2 interventional studies under Carcinoma, Basal Cell, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 67. This study's 25 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cotsiranib
Sirnaomics